Recent studies [41] have shown that medications such as SGLT2 inhibitors and angiotensin receptor–neprilysin inhibitors confer anti-inflammatory, antifibrotic, and renal-protective effects, which may be particularly advantageous in patients with HF, CKD, and AF. This evidence concerns the gene MME and hydrops fetalis.